Astrazeneca traded at $66.19 this Thursday August 18th, decreasing $0.24 or 0.35 percent since the previous trading session. Looking back, over the last four weeks, Astrazeneca lost 2.90 percent. Over the last 12 months, its price rose by 11.82 percent. Looking ahead, we forecast Astrazeneca to be priced at 64.84 by the end of this quarter and at 59.73 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
66.19
Daily Change
-0.35%
Yearly
11.82%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 141.27 -0.17 -0.12% 19.79%
Astrazeneca 66.19 -0.24 -0.35% 11.82%
Bristol-Myers Squibb 74.08 -0.48 -0.64% 8.13%
Corcept Therapeutics 27.03 0.02 0.07% 32.89%
Catalent 107.36 -1.04 -0.96% -11.20%
Endo International 0.33 0.04 15.36% -90.77%
Genmab 2,617.00 -39.00 -1.47% -11.86%
GlaxoSmithKline 1,402.00 -13.40 -0.95% -7.37%
Horizon Pharma 60.95 -0.79 -1.27% -40.96%
Jazz Pharmaceuticals 158.22 0.62 0.39% 20.31%
J&J 166.77 -0.81 -0.48% -6.61%
Lannett 0.57 -0.004 -0.61% -86.40%
Eli Lilly 316.26 -0.56 -0.18% 16.96%
Merck & Co 90.93 -0.11 -0.12% 15.89%
Novartis 81.03 -0.20 -0.25% -5.13%
Phibro Animal Health 18.23 -0.22 -1.19% -26.19%
Prestige Brands 56.33 0.60 1.08% -2.85%
Pacira 58.21 0.07 0.12% 6.51%
Pfizer 48.75 -0.52 -1.06% -0.10%
Powershares High Yield Orate Bond Portfolio 17.70 0.04 0.21% -9.11%
Perrigo 40.65 1.02 2.57% 2.26%
Drreddys Laboratories 52.76 0.57 1.09% -15.71%
Roche Holding 318.55 1.90 0.60% -14.37%
Sanofi 81.64 -0.03 -0.04% -9.46%
Supernus Pharmaceuticals 33.58 0.07 0.21% 42.65%
Teva Pharmaceutical Industries 10.34 0.33 3.30% 12.15%
United States Oil Fund 74.06 2.01 2.79% 65.42%
Bausch Health Companies Inc 7.37 -0.29 -3.73% -79.41%
Canopy Growth Corp 5.00 -0.23 -4.40% -76.37%
Zoetis 171.85 -0.61 -0.35% -16.76%


Astrazeneca
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.